natgillin/translations-raw huggingface dataset:
The use of claim 33, wherein said cancer is selected from colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, brain cancer, ovarian cancer, cervical cancer, testicular cancer, renal cancer, cancer of the head and neck, lymphoma, and leukemia. 
Upotreba prema patentnom zahtjevu 33, pri čemu je spomenuti rak izabran od raka debelog crijeva, raka gušterače, raka dojke, raka prostate, raka pluća, raka mozga, raka jajnika, raka grlića materice, raka testisa, raka bubrega, raka glave i vrata, limfoma i leukemije.
A compound of any one of claims 1 to 15 and 24 to 26, or a pharmaceutically acceptable salt thereof, or a solid form of any one of claims 16 to 23, for administration to said patient with an anti-viral agent, an anti-cancer vaccine, an anti-CTLA-4 antibody, a chemotherapeutic, an immunosuppressant, radiation, an anti-tumor vaccine, an anti-viral vaccine, cytokine therapy, or a tyrosine kinase inhibitor in a single dosage form or simultaneously or sequentially in separate dosage forms. 
Spoj prema bilo kojem od patentnih zahtjeva 1 do 15 i 24 do 26, ili njegova farmaceutski prihvatljiva sol, ili čvrsti oblik prema bilo kojem od patentnih zahtjeva 16 do 23, za davanje spomenutom pacijentu sa anti-virusnim sredstvom, vakcine protiv raka, anti-CTLA-4 antitijela, hemoterapeutika, imunosupresiva, zračenja, vakcine protiv tumora, vakcine protiv virusa, citokin terapije, ili inhibitor tirozin kinaze u jednom obliku za doziranje, ili istovremeno ili sekvencijalno u odvojenim dozirnim oblicima.
A compound, salt, or solid form for administration according to claim 35, wherein said chemotherapeutic is a cytotoxic agent. 
Spoj, sol ili čvrsti oblik za primjenu prema patentnom zahtjevu 35, pri čemu je spomenuti hemoterapeutik citotoksično sredstvo.
Insulin sensitizers selected from the group consisting of (i) PPAR agonists, (ii) biguanides, and (iii) protein phosphatase-1B inhibitors; 
inzulinske senzibilizatore odabrane iz skupine koja se sastoji od (i) PPAR agonista, (ii) bigvanida, te (iii) inhibitora protein fosfataze-1B;
Sulfonylureas or other insulin secretagogues; 
Sulfonilureje ili druge inzulinske sekretagoge;
Anti-obesity compounds; 
spojeve protiv pretilosti;
A pharmaceutical combination comprising the compound or the mixture of any of claims 1-5; and an antidiabetic agent that increases insulin secretion, increases insulin sensitivity, reduces the uptake of sugar from the gastrointestinal track, enhances the effect of endogenous peptides or proteins that affect glycemic control, provides a replacement for endogenous peptides or proteins that affect glycemic control, or any combination thereof. 
Farmaceutska kombinacija naznačena time da sadrži spoj prema bilo kojem zahtjevu od 1-6 ili pripravak prema zahtjevu 7; i antidijabetičko sredstvo koje povećava izlučivanje inzulina, povećava inzulinsku osjetljivost, smanjuje unos šećera iz gastrointestinalnog trakta, ili pojačava učinak peptida ili proteina koji utječu na kontrolu glikemije, ili bilo koja njihova kombinacija.
The pharmaceutical combination of claim 14 wherein the weight ratio of the compound and the antidiabetic agent is from about 0.01:1 to about 100:1. 
Farmaceutska kombinacija prema zahtjevu 14 naznačena time da je težinski omjer spoja i antidijabetičkog sredstva od oko 0.01:1 do oko 100:1.
The compound of claim 1 selected from: 
Spoj prema patentnom zahtjevu 1, izabran iz:
having at least three XRPD peaks, in terms of 2-theta, selected from about 18.4°, about 18.9°, about 21.8°, about 23.9°, about 29.2°, and about 38.7°. 
Čvrsti oblik spoja prema patentnom zahtjevu 15 koji ima najmanje tri XRPD pika, u uvjetima na 2-teta +/-0.2°, izabrana od 18.4°, 18.9°, 21.8°, 23.9°, 29.2°, i 38.7°.
A compound or salt of any one of claims 1-8 and 14-16, or a solid form of any one of claims 9-13, for use in inhibiting activity of indoleamine 2,3-dioxygenase, inhibiting immunosuppression, or treating cancer, viral infection, depression, a neurodegenerative disorder, trauma, age-related cataracts, organ transplant rejection, or an autoimmune disease in a patient. 
Spoj prema bilo kojem od patentnih zahtjeva 1 do 15 i 24 do 26, ili njegova farmaceutski prihvatljiva sol, ili čvrsti oblik prema bilo kojem od patentnih zahtjeva 16 do 23, za primjenu u liječenju raka, virusne infekcije, depresije, neurodegenerativnog poremećaja, traume, senilne katarakte, odbacivanja presađenog organa, ili autoimune bolesti kod pacijenta.
The compound, salt, or solid form for use according to claim 18, wherein said cancer is selected from melanoma, colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, brain cancer, ovarian cancer, cervical cancer, testicular cancer, renal cancer, cancer of the head and neck, lymphoma, and leukemia. 
Spoj, sol, ili čvrsti oblik za upotrebu prema patentnom zahtjevu 30, pri čemu je spomenuti rak izabran od raka debelog crijeva, raka gušterače, raka dojke, raka prostate, raka pluća, raka mozga, raka jajnika, raka grlića materice, raka testisa, raka bubrega, raka glave i vrata, limfoma i leukemije.
The compound, salt, or solid form for use according to claim 20, wherein said chemotherapeutic is a cytotoxic agent. 
Spoj, sol ili čvrsti oblik za primjenu prema patentnom zahtjevu 35, pri čemu je spomenuti hemoterapeutik citotoksično sredstvo.
The compound, salt, or solid form for use according to any one of claims 1 to 12, wherein said cancer is selected from melanoma, colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, brain cancer, ovarian cancer, cervical cancer, testicular cancer, renal cancer, cancer of the head and neck, lymphoma, and leukemia. 
Spoj, sol, ili čvrsti oblik za upotrebu prema patentnom zahtjevu 30, pri čemu je spomenuti rak izabran od raka debelog crijeva, raka gušterače, raka dojke, raka prostate, raka pluća, raka mozga, raka jajnika, raka grlića materice, raka testisa, raka bubrega, raka glave i vrata, limfoma i leukemije.
The composition or use according to any one of claims 1 to 11, wherein said compounds are formulated with a drug eluting polymer, a biomolecule, a micelle or liposome-forming lipids or oil in water emulsions, or pegylated or solid nanoparticles or microparticles for oral or parenteral or intratechal administration. 
Sastav u skladu s patentnim zahtjevom 1 ili 2, pri čemu su navedene tvari formulirane s biomolekulom, micelama ili lipidima koji stvaraju liposome ili uljima u vodenim emulzijama, ili pegiliranim ili čvrstim nanočesticama ili mikročesticama za oralnu ili parenteralnu ili intratekalnu primjenu.
Use of a compound according to claims 1 to 3 for the manufacture of a medicament for the treatment of a condition mediated by the AMPA-receptor. 
Uporaba spoja prema zahtjevima od 1 do 8, naznačena time, da služi u proizvodnji lijeka za liječenje epilepsije ili shizofrenije.
adding to the aqueous preparation one or more aldehyde-releasing biocides and/or biocides with one or more aldehyde groups in an amount such that the total amount of aldehyde-releasing biocides and/or biocides with one or more aldehyde groups in the aqueous preparation is from 250 ppm to 5000 ppm, calculated relative to the water in the preparation; 
dodavanje u vodeni pripravak jednog ili više biocida koji otpušta aldehid i/ili biocida s jednom ili više aldehidnih skupina u tolikoj količini da je ukupna količina biocida koji otpuštaju aldehid i/ili biocida s jednom ili više aldehidnih skupina u vodenom pripravku od 250 ppm do 5000 ppm, izračunata u odnosu na vodu u pripravku;
adding at least one water soluble lithium compound to the aqueous preparation in an amount such that the total amount of solubilised lithium in the aqueous preparation is from 1000 to 3000 ppm, calculated relative to the weight of water in the preparation, where steps (a) and (b) may be carried out simultaneously, or separately in any order and wherein the stabilization leads to a reduction of the cfu/ml value to a value of less than 104 cfu/ml, wherein the at least one water soluble lithium compound is a polymeric salt of lithium selected from the group consisting of acrylic homopolymers, acrylic copolymers such as copolymers of acrylic acid and maleic acid and/or acrylamide. 
dodavanje barem jednog litijevog sastojka topljivog u vodi u vodeni pripravak u količini tolikoj da je ukupna količina otopljenog litija u vodenom pripravku od 1000 do 3000 ppm, izračunato u odnosu na težinu vode u pripravku, pri čemu je litijev spoj topljiv u vodi polimerna sol litija izabrana od Li2Na2polifosfata ili litij-natrij heksametafosfata, gdje koraci (a) i (b) mogu biti izvedeni istovremeno, ili odvojeno bilo kojim redoslijedom te pri čemu stabilizacija dovodi do smanjenja vrijednosti cfu/mL na vrijednost manju od 104 cfu/mL,
Process according to claim 1, wherein said aldehyde-releasing biocide and/or biocide with one or more aldehyde groups and said soluble lithium compound are added separately to the aqueous preparation. 
Postupak u skladu s patentnim zahtjevom 1, pri čemu su navedeni biocid koji otpušta aldehid i/ili biocid s jednom ili više aldehidnih skupina i navedeni topljivi litijev sastojak zasebno dodani u vodeni pripravak.
Process according to claims 1 or 2, wherein said soluble lithium compound is added before said aldehyde-releasing biocide and/or biocide with one or more aldehyde groups. 
Postupak u skladu s patentnim zahtjevima 1 ili 2, pri čemu je navedeni topljivi litijev sastojak dodan prije navedenog biocida koji otpušta aldehid i/ili biocida s jednom ili više aldehidnih skupina.
Process according to claims 1 or 2, wherein said aldehyde-releasing biocide and/or biocide with one or more aldehyde groups is added before said soluble lithium compound. 
Postupak u skladu s patentnim zahtjevima 1 ili 2, pri čemu je navedeni biocid koji otpušta aldehid i/ili biocid s jednom ili više aldehidnih skupina dodan prije topljivog litijevog sastojka.
Process according to any of claims 1 to 5, wherein the biocide with one or more aldehyde groups is selected from the group comprising formaldehyde, acetaldehyde, glyoxal, glutaraldehyde, 2-propenal, phthalic dialdehyde and mixtures thereof, and preferably is formaldehyde, glutaraldehyde or a mixture thereof. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 5, pri čemu je biocid s jednom ili više aldehidnih skupina odabran iz grupe koja obuhvaća formaldehid, acetaldehid, glioksal, glutaraldehid, 2-propenal, ftalni dialdehid i njihove smjese, poželjno formaldehid, glutaraldehid ili njihova smjesa.
Process according to any of claims 7 to 10, wherein the aldehyde-releasing biocide and/or biocide with one or more aldehyde groups is added to the aqueous preparation in an amount of from 750 ppm to 4000 ppm, preferably in amount of from 1500 ppm to 3000 ppm, calculated relative to the weight of water in the preparation. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 8, pri čemu se biocid koji otpušta aldehid i/ili biocid s jednom ili više aldehidnih skupina dodaje u vodeni pripravak u količini od 750 ppm do 4000 ppm, poželjno u količini od 1500 ppm do 3000 ppm, izračunato u odnosu na težinu vode u pripravku.
Process according to any of claims 7 to 11, wherein the at least one source of a water soluble lithium compound is added to the aqueous preparation in an amount such that the total amount of solubilised lithium in the aqueous preparation is from 1500 to 2500 ppm, calculated relative to the weight of water in the preparation. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 10, pri čemu je barem jedan izvor litijevog spoja topljivog u vodi dodan u vodeni pripravak u tolikoj količini da je ukupna količina otopljenog litija u vodenom pripravku od 1500 do 2500 ppm, izračunato u odnosu na težinu vode u pripravku.
Process according to any of claims 1 to 13, wherein said natural calcium carbonate, synthetic, precipitated calcium carbonate, kaolin, talcum, aluminium hydroxide, aluminium silicate, titanium dioxide or mixtures thereof is selected from natural and/or synthetic calcium carbonate. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 12, pri čemu je navedeni prirodni kalcijev karbonat, sintetski, istaloženi kalcijev karbonat, kaolin, talk, aluminijev hidroksid, aluminijev salicilat, titanijev dioksid ili njihova smjesa odabran između prirodnog i/ili sintetskog kalcijevog karbonata.
Process according to any of claims 1 to 13, wherein steps a) and/or b) are repeated one or more times in order to maintain the concentration of the one or more aldehyde-releasing biocides and/or biocides with one or more aldehyde groups and/or the concentration of the solubilised lithium within the respective defined concentration ranges. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 13, pri čemu se koraci a) i/ili b) ponavljaju jedan ili više puta kako bi održali koncentraciju jednog ili više biocida koji otpušta aldehid i/ili biocida s jednom ili više aldehidnih skupina i/ili koncentraciju otopljenog litija unutar odgovarajućih definiranih koncentracijskih raspona.
The use according to claim 16, wherein the aqueous preparation is a dispersion or suspension of natural calcium carbonate, synthetic, precipitated calcium carbonate, kaolin, talcum, aluminium hydroxide, aluminium silicate, titanium dioxide or mixtures thereof, fillers or pigments. 
Uporaba u skladu s patentnim zahtjevom 15 i 16, pri čemu je vodeni pripravak disperzija ili suspenzija prirodnog kalcijevog karbonata, sintetskog, istaloženog kalcijevog karbonata, kaolina, talka, aluminijevog hidroksida, aluminijevog silikata, titanijevog dioksida ili njihovih smjesa, punila ili pigmenata.
A composition providing biocidal activity in aqueous preparations, the composition comprising: 
Sastav koji omogućuje biocidnu aktivnost u vodenim pripravcima, sastav obuhvaća:
Composition according to claim 18, wherein the biocide with one or more aldehyde groups is selected from the group comprising formaldehyde, acetaldehyde, glyoxal, glutaraldehyde, 2-propenal, phthalic dialdehyde and mixtures thereof, and preferably is formaldehyde, glutaraldehyde or a mixture thereof. 
Sastav u skladu s patentnim zahtjevom 18, pri čemu je biocid s jednom ili više aldehidnih grupa odabran iz grupe koja obuhvaća formaldehid, acetaldehid, glioksal, glutaraldehid, 2-propenal, ftalni dialdehid i njihove smjese, i poželjno je formaldehid, glutaraldehid ili njihova smjesa.
A method of decoding video, the method comprising: 
Postupak dekodiranja video slike, postupak obuhvaća:
The system according to claim 1, characterized in that the fans (3) installed at the entry to the lateral ventilation ducts are axial/diagonal with a system for separation of solid particles, whereas the fans (3a) installed at the entry to the middle ventilation duct are reversible/axial. 
Sustav prema zahtjevu 1, naznačen time da ventilatori (3) smješteni u bočnim ventilacijskim kanalima su aksijalno - dijagonalni ventilatori sa sistemom za odvajanje krutih čestica, a ventilatori (3a) smješteni u srednjem ventilacijskom kanalu su reverzibilni aksijalni ventilatori.
The system according to claim 1, characterized in that the tank (9) contains pressurized air with reduced oxygen content. 
Sustav prema zahtjevu 1, naznačen time da spremnik (9) sadrži stlačeni zrak sa reduciranim udjelom kisika.
The system according to claim 6, characterized in that the tank (9) contains any other fire-fighting gas agent. 
Sustav prema zahtjevu 6, naznačen time da spremnik (9) sadrži bilo koje drugo plinovito sredstvo za gašenje požara.
The system according to any of the preceding claims, characterized in that in fire conditions the middle duct serves for the removal of contaminated air and smoke from the tunnel, where in the event of fire in the section located closer to one of the portals said middle duct serves to bring fresh air. 
Sustav prema bilo kojem od prethodnih zahtjeva, naznačen time da srednji kanal u uvjetima požara služi za odvođenje zagađenog zraka i dima iz tunela, pri čemu u slučaju požara u odsjeku koji se nalazi bliže jednom od portala služi za dovođenje zraka.
The ventilation and fire-fighting process in the tunnel in normal and in fire conditions through the system defined under the claims 1 to 9, where the maximum permissible designed air quantity qmax is defined for tunnel ventilation in normal conditions and in fire conditions, where said process involves steps of: 
Postupak ventilacije i gašenja požara u normalnim uvjetima i u uvjetima požara u tunelu putem sustava definiranog zahtjevima 1 do 9, pri čemu se definira maksimalno dozvoljena projektirana količina zraka qmax za ventilaciju tunela u normalnim uvjetima i u požarnim uvjetima, pri čemu navedeni postupak sadrži slijedeće korake:
measurement of air velocity v at maximum distance of 50 m from the entry to the tunnel, and switching on or off air screens (6a) by means of the fan (6) on the traffic part of at least one portal; and 
mjerenje brzina zraka v na najviše 50 m od ulaza u tunel, te uključivanje odnosno isključivanje zračnih zavjesa (6a) pomoću ventilatora (6) na način da dozvoljavaju ulaz zraka kroz portale u tunel samo do maksimalne projektirane količine zraka qmax koju mogu odsisati ugrađeni ventilatori (3, 3a), te
simultaneous measurement of air velocity v in the tunnel at every 300 to 500 metres, where, depending on the air velocity v, the probes (8) control the operation capacity of the fans (3) and (3a) mounted in the engine rooms on the tunnel portals at the entry to the ventilation ducts; and 
istovremeno mjerenje brzine zraka v u tunelu na svakih 300 do 500 m, pri čemu, ovisno o brzini zraka v, sonde (8) upravljaju kapacitetom rada ventilatora (3) i (3a) smještenih u strojarnicama na portalima tunela, te
simultaneous measurement of O2, CO values and air visibility in the tunnel by means of the probes (13), where the probes (13) control the operation capacity of the fans (3) and (3 a) at the entry to the ventilation ducts, and, depending on the values of the measured parameters, uniform aspiration of air out of the tunnel by means of the lateral ventilation ducts is performed, whereby the supply of minimum required fresh air quantity is continuously provided through the traffic part of the portals; and 
istovremeno mjerenje koncentracije O2, CO i vidljivosti zraka u tunelu pomoću sondi (13), pri čemu se navedenim sondama (13) upravlja ventilatorima (3) i (3a), te ovisno 0 koncentraciji mjerenih parametara jednoliko odvođenje zraka iz tunela putem bočnih ventilacijskih kanala čime se kroz portale kontinuirano osigurava dotok minimalno potrebne količine svježeg zraka, i
The process according to claim 10, characterized in that after detection of fire conditions in a section nearer to the middle of the tunnel, the adjacent flaps (5) bounding the fire zone will close the duct profile in such a way that they will direct the air and smoke motion through the middle ventilation duct towards the tunnel exit, whereas the other flaps (5) in the middle duct are closed, and the fans (3a) at the entry to the ventilation ducts on both portals operate by way of carrying air and smoke away from the fire zone, where the air screen (6a) starts operating if air velocity v on at least one of the portals rises above the designed velocity v2. 
Postupak prema zahtjevu 10, naznačen time da detektiranjem uvjeta požara u odsjeku koji se nalazi u području sredine tunela, susjedne klapne (5) koje omeđuju požarni odsjek zatvaraju presjek kanala na način da usmjeravaju strujanje zraka i dima kroz srednji ventilacijski kanal prema izlazu iz tunela dok su ostale klapne (5) u srednjem kanalu spuštene, te ventilatori (3a) na oba portala rade na način da odvode zrak i dim iz požarnog odsjeka, pri čemu se zračna zavjesa (6a) uključuje u slučaju da brzina v na barem jednom od portala poraste iznad projektirane brzine V2.
The process according to claims 10, 12 and 13, characterized in that after detecting fire conditions in any area of the tunnel, the adjacent flaps (4) bounding the fire zone will restrict the profile of the lateral ducts by way of directing the air and smoke motion through the lateral ventilation ducts towards the tunnel exit, whereas the other flaps (5) in the middle duct are closed, and the fans (3) at the entry to the ventilation ducts on both portals operate by way of carrying air and smoke away from the fire zone, where the air screen (6a) starts operating if air velocity v on at least one of the portals rises above the designed velocity v2. 
Postupak prema zahtjevima 10, 12 i 13, naznačen time da nakon detektiranjem uvjeta požara u bilo kojem području tunela susjedne klapne (4), koje omeđuju požarni odsjek, ograničavaju presjek bočnih kanala na način da usmjeravaju strujanje zraka i dima kroz bočne ventilacijske kanale prema izlazu iz tunela dok su ostale klapne (5) u srednjem kanalu spuštene, te ventilatori (3) na oba portala rade na način da odvode zrak i dim iz požarnog odsjeka, pri čemu se zračna zavjesa (6a) uključuje u slučaju da brzina v najednom od portala poraste iznad projektirane brzine V2.
The bispecific antibody of claim 1, wherein the bispecific antibody is a dimeric molecule comprising a first antibody comprising the first antigen binding site specific for DR5 and a second antibody comprising the second antigen binding site specific for FAP. 
Bispecifično protutijelo prema zahtjevu 1, naznačeno time, da bispecifično protutijelo je dimerna molekula koja obuhvaća prvo protutijelo koje sadrži prvo mjesto vezanja antigena specifičnog za DR5 i drugo protutijelo koje sadrži drugo mjesto vezanja antigena specifičnog za FAP.
The bispecific antibody of claim 2, wherein the first antibody is an Immunoglobulin (Ig) molecule comprising a light chain and a heavy chain and the second antibody is selected from the group consisting of scFv, scFab, Fab or Fv. 
Bispecifično protutijelo prema zahtjevu 2, naznačeno time, da je prvo protutijelo molekula imunoglobulina (Ig) koja sadrži slabi lanac i jaki lanac a drugo protutijelo je odabrano iz skupine koja se sastoji od scFv, scFab, Fab ili Fv.
The bispecific antibody of any of claims 5-8, wherein the second molecule is fused to the Ig molecule by a peptide linker, preferably a peptide linker having a length of about 10 - 30 amino acids. 
Bispecifično protutijelo prema bilo kojem od zahtjeva 5 do 8, naznačeno time, da je druga molekula sraštena na Ig-molekulu preko peptidne poveznice, gdje peptidna poveznica ima duljinu poželjno od oko 10 – 30 aminokiselina.
A pharmaceutical composition comprising a bispecific antibody of claims 1 to 11. 
Farmaceutski sastav, naznačen time, da obuhvaća bispecifično protutijelo prema zahtjevima od 1 do 11.
A method for preparing a compound of formula (III), or salt thereof, wherein 
Postupak za proizvodnju spoja formule (III) ili njegove soli, [image] gdje
is C1-C7-alkyl, such as methyl or ethyl; or is unsubstituted C6-C10-aryl such as phenyl; or is C6C10-aryl substituted by one or more substituents independently selected from C1-C7-alkyl, C1-C7-alkoxy-C1-C7-alkyl, C1-C7-alkoxy or halo, such as para-chlorophenyl; consisting of reacting a compound of formula (IV), or salt thereof, wherein R1 is as defined for the compound of formula (III), under decarboxylation reaction conditions which are achieved by heating, to provide the compound of formula (III). 
je C1-C7-alkil, kao što je metil ili etil; ili je nesupstituirani C6-C10-aril kao što je fenil; ili je C6-C10-aril supstituiran s jednim ili više supstituenata neovisno odabranih od sljedećih: -C7-alkil, C1-C7-alkoksi-C1-C7-alkil, C1-C7-alkoksi ili halogen, kao što je para-klorofenil; naznačen time, da se sastoji od reakcije spoja formule (IV) ili njegove soli, [image] gdje R1 je kao što je definiran za spoj formule (III), pod uvjetima dekarboksilacijske reakcije koja se postiže zagrijavanjem, u svrhu dobivanja spoja formule (III).
The process according to claim 1, wherein the decarboxylation reaction conditions are achieved by heating at a temperature of from 80 deg C to 250 deg C. 
Postupak prema zahtjevu 1, naznačen time, da se uvjeti za dekarboksilacijsku reakciju postižu zagrijavanjem na temperaturi od 80°C do 250°C.